PR positive

About

Biomarker Type: Protein expression

Present: True

Marker: Progesterone receptor (PR)

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) HSE (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HSE (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
HSE (2) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole
HSE (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole
HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HPRA (3) HSE (3) ER positive, PR positive Invasive Breast Carcinoma Letrozole
HPRA (3) HSE (3) PR positive Invasive Breast Carcinoma Letrozole
HSE (1) ER positive, PR positive Invasive Breast Carcinoma Exemestane
HSE (1) PR positive Invasive Breast Carcinoma Exemestane
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HPRA (3) HSE (1) PR positive Invasive Breast Carcinoma Anastrozole
HPRA (3) HSE (1) ER positive, PR positive Invasive Breast Carcinoma Anastrozole
HPRA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
HPRA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan